Nicole DeFeudis is an Editor at Endpoints News. She specializes in biopharma reporting, focusing on themes such as pharmaceuticals, healthcare technology, and consumer health. Nicole has been featured in New England Public Media, World Wealth Journal, and multiple publications under Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nicole's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly around regulatory approvals, legal policy regulation, and government announcements. She appears to be interested in stories related to FDA approvals, drug pricing, mergers and acquisitions within the pharmaceutical space.
To effectively reach out to Nicole with a pitch or as a source for her articles, it would be beneficial to provide insights or expertise related to recent developments in FDA regulations and approvals, legal challenges faced by pharmaceutical companies such as patent disputes or antitrust issues. Additionally, commentary on the implications of regulatory changes on drug pricing could also resonate well with her coverage focus.
It is important to note that Nicole tends to cover topics without geographic constraints explicitly mentioned. Therefore, pitches should focus on providing broader industry-specific insights rather than region-specific news unless otherwise indicated.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nicole Defeudis
Takeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring.
By: Nicole Defeudis
Candel Therapeutics' CEO says long-term data bode well for its prostate cancer drug aglatimagene ahead of an FDA submission.
By: Nicole Defeudis
Amgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program.
By: Nicole DeFeudis, Max Gelman
Welcome back to Endpoints Weekly. The biggest news this week was Marty Makary's resignation from his role as FDA Commissioner. The announcement came days after …
The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca, J&J, Bristol Myers Squibb, Novo Nordisk and Boehringer Ingelheim.
By: Max Gelman, Nicole DeFeudis
Welcome back to Endpoints Weekly! We've got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author …
By: Nicole Defeudis
Priority review voucher prices have roughly doubled in recent years, with 2026 sales hitting $180 million to $205 million.
By: Nicole Defeudis
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
By: Nicole Defeudis
Eli Lilly threatens to cut 340B discounts for hospitals that won't share claims data, as the American Hospital Association calls the policy illegal.
Axsome has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040.
